Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Esophageal Neoplasms 2Recurrence 1Non-small Cell Lung Cancer Metastatic 1Nasopharyngeal Carcinoma 1NSCLC 1Lymphoma, T-Cell 1Immunoblastic Lymphadenopathy 1Carcinoma, Non-Small-Cell Lung 1Advanced Gastric Adenocarcinoma 1

Interventions

Radiotherapy 10fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 8Cyclosporine 7Cyclophosphamide 7Busulfan 7Whole-Body Irradiation 6Melphalan 6Radiofrequency Ablation 5Mycophenolic Acid 5Filgrastim 5Antilymphocyte Serum 5Surveys and Questionnaires 4Surgical Procedures, Operative 4Methotrexate 4Etoposide 4Drug Therapy 4Cisplatin 4fludarabine 3Radiosurgery 3Injections 3Hepatectomy 3Cord Blood Stem Cell Transplantation 3thymoglobulin 2lenvatinib 2Vinblastine 2Videotape Recording 2Thiotepa 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recurrence × spartalizumab × Clear all
NCT03914352 2019-04-16

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Cancer Hospital of Guangxi Medical University

Phase NA Unknown
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡